Can a targeted drug combo beat the toughest childhood leukemia?

NCT ID NCT06257394

Recruiting now ⭐️ CURE ⭐️ Sponsor: Hyoung Jin Kang Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding dasatinib and blinatumomab to standard chemotherapy can improve outcomes for children aged 1 to 19 with very high-risk acute lymphoblastic leukemia. The study focuses on patients with specific genetic markers or who did not respond to initial treatment. The goal is to see if this approach can prevent relapse and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dasatinib (Sprycel) and blinatumomab
What this could lead to: If successful, this approach could improve survival and reduce relapse in children with the most aggressive forms of leukemia.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. The treatments carry risks like infection and organ toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia childhood acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA, PEDIATRIC

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Chonnam National University Hwasun Hospital
RECRUITING

Hwasun, 58128, South Korea
Chungnam National University Hospital
RECRUITING

Daejeon, 35015, South Korea
Jeju National University Hospital
RECRUITING

Jeju City, 63241, South Korea
Kyungpook National University Chilgok-Hospital
RECRUITING

Daegu, 41404, South Korea
Pusan National University Yangsan Hospital
RECRUITING

Yangsan, 50612, South Korea
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Seoul saint Mary's Hospital
RECRUITING

Seoul, 06591, South Korea
Severance Hospital
RECRUITING

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.